Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Animesh Pardanani, Jason Gotlib, Catriona Jamieson, et al.
Journal of Clinical Oncology (2011) Vol. 29, Iss. 7, pp. 789-796
Open Access | Times Cited: 397

Showing 1-25 of 397 citing articles:

Mutations and prognosis in primary myelofibrosis
A. M. Vannucchi, T L Lasho, Paola Guglielmelli, et al.
Leukemia (2013) Vol. 27, Iss. 9, pp. 1861-1869
Closed Access | Times Cited: 717
JAK/STAT signaling in hematological malignancies
William Vainchenker, Stefan N. Constantinescu
Oncogene (2012) Vol. 32, Iss. 21, pp. 2601-2613
Open Access | Times Cited: 477
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Robert Roskoski
Pharmacological Research (2019) Vol. 152, pp. 104609-104609
Closed Access | Times Cited: 476
Biology and significance of the JAK/STAT signalling pathways
Hiu Kiu, Sandra E. Nicholson
Growth Factors (2012) Vol. 30, Iss. 2, pp. 88-106
Open Access | Times Cited: 432
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
Animesh Pardanani, Claire Harrison, Jorge E. Cortés, et al.
JAMA Oncology (2015) Vol. 1, Iss. 5, pp. 643-643
Closed Access | Times Cited: 412
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
Robyn M. Emanuel, Amylou C. Dueck, Holly L. Geyer, et al.
Journal of Clinical Oncology (2012) Vol. 30, Iss. 33, pp. 4098-4103
Open Access | Times Cited: 405
Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
Priya Koppikar, Neha Bhagwat, Outi Kilpivaara, et al.
Nature (2012) Vol. 489, Iss. 7414, pp. 155-159
Open Access | Times Cited: 348
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Ayalew Tefferi, Francisco Cervantes, Ruben A. Mesa, et al.
Blood (2013) Vol. 122, Iss. 8, pp. 1395-1398
Open Access | Times Cited: 339
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Pietro Ciceri, Susanne Müller, Alison O’Mahony, et al.
Nature Chemical Biology (2014) Vol. 10, Iss. 4, pp. 305-312
Open Access | Times Cited: 330
Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies
Ayalew Tefferi, William Vainchenker
Journal of Clinical Oncology (2011) Vol. 29, Iss. 5, pp. 573-582
Closed Access | Times Cited: 318
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Robert Roskoski
Pharmacological Research (2016) Vol. 111, pp. 784-803
Closed Access | Times Cited: 307
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
Ayalew Tefferi, Terra L. Lasho, Kebede H. Begna, et al.
New England Journal of Medicine (2015) Vol. 373, Iss. 10, pp. 908-919
Open Access | Times Cited: 305
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 34, pp. 3844-3850
Open Access | Times Cited: 305
Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
Alfonso Quintás‐Cardama, Srđan Verstovšek
Clinical Cancer Research (2013) Vol. 19, Iss. 8, pp. 1933-1940
Open Access | Times Cited: 263
EZH2 mutational status predicts poor survival in myelofibrosis
Paola Guglielmelli, Flavia Biamonte, Joannah Score, et al.
Blood (2011) Vol. 118, Iss. 19, pp. 5227-5234
Open Access | Times Cited: 256
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
Animesh Pardanani, Rebecca R. Laborde, Terra L. Lasho, et al.
Leukemia (2013) Vol. 27, Iss. 6, pp. 1322-1327
Open Access | Times Cited: 225
One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
Ayalew Tefferi, Terra L. Lasho, Thitina Jimma, et al.
Mayo Clinic Proceedings (2012) Vol. 87, Iss. 1, pp. 25-33
Open Access | Times Cited: 218
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue Chen, Qinfan Yao, Xinyu Gu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 214
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
Daniela Sia, Victoria Tovar, Agrin Moeini, et al.
Oncogene (2013) Vol. 32, Iss. 41, pp. 4861-4870
Open Access | Times Cited: 213
Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors
S.W. Ember, Jin-Yi Zhu, S.H. Olesen, et al.
ACS Chemical Biology (2014) Vol. 9, Iss. 5, pp. 1160-1171
Open Access | Times Cited: 208
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19
Farhad Seif, Hossein Aazami, Majid Khoshmirsafa, et al.
International Archives of Allergy and Immunology (2020) Vol. 181, Iss. 6, pp. 467-475
Open Access | Times Cited: 195
Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation
Florian Perner, Caroline Perner, Thomas Ernst, et al.
Cells (2019) Vol. 8, Iss. 8, pp. 854-854
Open Access | Times Cited: 188
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
Moshe Talpaz, Jean‐Jacques Kiladjian
Leukemia (2020) Vol. 35, Iss. 1, pp. 1-17
Open Access | Times Cited: 146
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 89
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Aaron T. Gerds, Jason Gotlib, Haris Ali, et al.
Journal of the National Comprehensive Cancer Network (2022) Vol. 20, Iss. 9, pp. 1033-1062
Open Access | Times Cited: 82
Page 1 - Next Page

Scroll to top